Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117


Quantification of biological age as a determinant of age-related diseases in the Rotterdam Study: a structural equation modeling approach.

Waziry R, Gras L, Sedaghat S, Tiemeier H, Weverling GJ, Ghanbari M, Klap J, de Wolf F, Hofman A, Ikram MA, Goudsmit J.

Eur J Epidemiol. 2019 Aug;34(8):793-799. doi: 10.1007/s10654-019-00497-3. Epub 2019 Apr 13.


In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice.

Sutton TC, Lamirande EW, Bock KW, Moore IN, Koudstaal W, Rehman M, Weverling GJ, Goudsmit J, Subbarao K.

J Virol. 2017 Nov 30;91(24). pii: e01603-17. doi: 10.1128/JVI.01603-17. Print 2017 Dec 15.


Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections.

Vegvari C, Cauët E, Hadjichrysanthou C, Lawrence E, Weverling GJ, de Wolf F, Anderson RM.

PLoS One. 2016 Jun 22;11(6):e0156622. doi: 10.1371/journal.pone.0156622. eCollection 2016.


A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.

Van Wesenbeeck L, D'Haese D, Tolboom J, Meeuws H, Dwyer DE, Holmes M, Ison MG, Katz K, McGeer A, Sadoff J, Weverling GJ, Stuyver L.

Open Forum Infect Dis. 2015 Nov 3;2(4):ofv166. doi: 10.1093/ofid/ofv166. eCollection 2015 Dec.


Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans.

Roozendaal R, Tolboom J, Roos A, Riahi S, Theeuwsen J, Bujny MV, Klaren V, Korse HJ, Dekking L, Grootenhuis A, Weverling GJ, Koudstaal W, Goudsmit J, Radošević K.

PLoS One. 2014 Jul 30;9(7):e103550. doi: 10.1371/journal.pone.0103550. eCollection 2014.


Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.

Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D, Weijtens M, Grazia Pau M, Radošević K, Weverling GJ, Custers J, Vellinga J, Schuitemaker H, Goudsmit J, Rodríguez A.

PLoS One. 2012;7(12):e44115. doi: 10.1371/journal.pone.0044115. Epub 2012 Dec 6.


The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.

Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV.

Vaccine. 2012 Nov 19;30(49):7005-12. doi: 10.1016/j.vaccine.2012.09.069. Epub 2012 Oct 8.


Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.

Kostense S, Moore S, Companjen A, Bakker AB, Marissen WE, von Eyben R, Weverling GJ, Hanlon C, Goudsmit J.

Antimicrob Agents Chemother. 2012 Jul;56(7):3524-30. doi: 10.1128/AAC.06179-11. Epub 2012 Apr 30.


Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H.

Vaccine. 2011 Oct 19;29(45):8049-59. doi: 10.1016/j.vaccine.2011.08.042. Epub 2011 Aug 22.


International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J.

Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.


The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17. doi: 10.1164/rccm.200910-1484OC. Epub 2010 Feb 18.


New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J.

PLoS One. 2010 Feb 8;5(2):e9106. doi: 10.1371/journal.pone.0009106.


Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.

Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, Goudsmit J.

J Infect Dis. 2009 Dec 15;200(12):1870-3. doi: 10.1086/648378.


First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.

Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling GJ, Uytdehaag F, Herzog C, Briggs DJ, Rupprecht CE, Grimaldi R, Goudsmit J.

Vaccine. 2008 Nov 5;26(47):5922-7. doi: 10.1016/j.vaccine.2008.08.050. Epub 2008 Sep 17.


Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2008 Jul 4;26(29-30):3640-6. doi: 10.1016/j.vaccine.2008.04.071. Epub 2008 May 15.


Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.


Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2007 Nov 28;25(49):8338-45. Epub 2007 Oct 15.


A sensitive cell-based assay for the detection of residual infectious West Nile virus.

Koldijk MH, Bogaards JA, Kostense S, de Vocht M, Gijsbers L, Ter Haak M, Ophorst C, Brakenhoff JP, Weverling GJ, Guichoux JY, Uytdehaag F, Lewis J, Goudsmit J, Marzio G.

Vaccine. 2007 Sep 28;25(39-40):6872-81. Epub 2007 Jul 27.


Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.


Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr.

Infect Immun. 2007 May;75(5):2283-90. Epub 2007 Feb 16.


A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.

Marzio G, Kerkvliet E, Bogaards JA, Koelewijn S, De Groot A, Gijsbers L, Weverling GJ, Vogels R, Havenga M, Custers J, Pau MG, Guichoux JY, Lewis J, Goudsmit J.

Vaccine. 2007 Mar 8;25(12):2228-37. Epub 2006 Dec 28.


Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH.

J Clin Microbiol. 2006 Oct;44(10):3781-3.


Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method.

Kapteyn JC, Saidi MD, Dijkstra R, Kars C, Tjon JC, Weverling GJ, de Vocht ML, Kompier R, van Montfort BA, Guichoux JY, Goudsmit J, Lagerwerf FM.

Vaccine. 2006 Apr 12;24(16):3137-44. Epub 2006 Feb 6.


Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors.

Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M, van Leuven K, Que I, Ouwehand K, Mintardjo R, Weverling GJ, Radosevic K, Richardson J, Eloit M, Lowik C, Quax P, Havenga M.

J Gen Virol. 2006 Feb;87(Pt 2):255-65.


Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding.

Bogaards JA, Weverling GJ, Zwinderman AH, Bossuyt PM, Goudsmit J.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):232-7.


Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease.

Biezeveld MH, Geissler J, Weverling GJ, Kuipers IM, Lam J, Ottenkamp J, Kuijpers TW.

Arthritis Rheum. 2006 Jan;54(1):369-76.


Increased incidence of cancer in adult Gaucher disease in Western Europe.

de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE.

Blood Cells Mol Dis. 2006 Jan-Feb;36(1):53-8. Epub 2005 Oct 24.


Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.

Casula M, Weverling GJ, Wit FW, Timmermans EC, Stek M Jr, Lange JM, Reiss P.

J Infect Dis. 2005 Nov 15;192(10):1794-800. Epub 2005 Oct 12.


Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?

Leroy V, Sakarovitch C, Cortina-Borja M, McIntyre J, Coovadia H, Dabis F, Newell ML, Saba J, Gray G, Ndugwa Ch, Kilewo Ch, Massawe A, Kituuka P, Okong P, Grulich A, von Briesen H, Goudsmit J, Biberfeld G, Haverkamp G, Weverling GJ, Lange JM; Ghent Group on HIV in Women and Children.

AIDS. 2005 Nov 4;19(16):1865-75.


Community-acquired pathogens associated with prolonged coughing in children: a prospective cohort study.

Versteegh FG, Weverling GJ, Peeters MF, Wilbrink B, Veenstra-van Schie MT, van Leeuwen-Gerritsen JM, Mooi-Kokenberg EA, Schellekens JF, Roord JJ.

Clin Microbiol Infect. 2005 Oct;11(10):801-7.


Recurrence after segmental resection for colonic Crohn's disease.

Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA.

Br J Surg. 2005 Sep;92(9):1143-9.


Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study.

Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, Brown J, Phillips A, Otte JB, Czauderna P, MacKinlay G, Vos A.

J Clin Oncol. 2005 Feb 20;23(6):1245-52.


Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis.

Cahen DL, van Berkel AM, Oskam D, Rauws EA, Weverling GJ, Huibregtse K, Bruno MJ.

Eur J Gastroenterol Hepatol. 2005 Jan;17(1):103-8.


Adiponectin and glucose production in patients infected with Plasmodium falciparum.

Blümer RM, van Thien H, Ruiter AF, Weverling GJ, vinh Thuan D, Endert E, Kager PA, Sauerwein HP.

Metabolism. 2005 Jan;54(1):60-6.


Gluconeogenesis and fasting in cerebral malaria.

van Thien H, Ackermans MT, Weverling GJ, Dang Vinh T, Endert E, Kager PA, Sauerwein HP.

Neth J Med. 2004 Apr;62(4):129-33.


Free fatty acids increase hepatic glycogen content in obese males.

Allick G, Sprangers F, Weverling GJ, Ackermans MT, Meijer AJ, Romijn JA, Endert E, Bisschop PH, Sauerwein HP.

Metabolism. 2004 Jul;53(7):886-93.


Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.

van der Valk M, Allick G, Weverling GJ, Romijn JA, Ackermans MT, Lange JM, van Eck-Smit BL, van Kuijk C, Endert E, Sauerwein HP, Reiss P.

J Clin Endocrinol Metab. 2004 Jul;89(7):3554-60.


Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.

ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD.

Lancet. 2004 Jun 26;363(9427):2139-41.


Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J.

AIDS. 2004 May 21;18(8):1213-6.


An IL-8 gene promoter polymorphism is associated with the risk of the development of AIDS-related Kaposi's sarcoma: a case-control study.

van der Kuyl AC, Polstra AM, Weverling GJ, Zorgdrager F, van den Burg R, Cornelissen M.

AIDS. 2004 May 21;18(8):1206-8.


FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria.

van Thien H, Weverling GJ, Ackermans MT, canh Hung N, Endert E, Kager PA, Sauerwein HP.

Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E609-15. Epub 2004 May 27.


Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study.

Assies J, Lok A, Bockting CL, Weverling GJ, Lieverse R, Visser I, Abeling NG, Duran M, Schene AH.

Prostaglandins Leukot Essent Fatty Acids. 2004 Apr;70(4):349-56.


Influence of prolonged starvation on glucose kinetics in pregnant patients infected with Plasmodium falciparum.

van Thien H, Ackermans MT, Weverling GJ, Thanh Chien VO, Endert E, Kager PA, Sauerwein HP.

Clin Nutr. 2004 Feb;23(1):59-67.


Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.

Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T.

Thorax. 2004 Feb;59(2):130-5.


TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JM.

AIDS. 2003 Dec 5;17(18):2623-7.


Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia.

Millo JL, Schultz MJ, Williams C, Weverling GJ, Ringrose T, Mackinlay CI, van der Poll T, Garrard CS.

Intensive Care Med. 2004 Jan;30(1):68-74. Epub 2003 Nov 21.


AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination.

van Ballegooijen M, Bogaards JA, Weverling GJ, Boerlijst MC, Goudsmit J.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):214-20.


Interferon-gamma increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients.

de Metz J, Romijn JA, Endert E, Ackermans MT, Weverling GJ, Busch OR, de Wit LT, Gouma DJ, ten Berge IJ, Sauerwein HP.

J Appl Physiol (1985). 2004 Feb;96(2):597-603. Epub 2003 Sep 23.


Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods.

Alioum A, Cortina-Borja M, Dabis F, Dequae-Merchadou L, Haverkamp G, Hughes J, Karon J, Leroy V, Newell ML, Richardson BA, van Weert L, Weverling GJ; Ghent Group.

Am J Epidemiol. 2003 Sep 15;158(6):596-605.

Supplemental Content

Loading ...
Support Center